Outlook Therapeutics is developing antibody-based therapeutics for ophthalmic disorders. Wet age-related macular degeneration (Wet AMD) is the leading cause of vision loss among people over age 50 and is triggered by abnormal blood vessel growth. Bevacizumab-vikg is a recombinant humanized monoclonal antibody that antagonizes the activity of the protein VEGF, a protein that regulates blood vessel formation. Outlook is developing the first ophthalmic formulation of bevacizumab that can be delivered to patients via intravitreal injection. Following injection and VEGF inhibition, vascular leakage can be reduced with the potential of deploying the therapy for patients with wet AMD.

Outlook Therapeutics

Founded: 2011
Location: Iselin, NJ
Employee range: 1-50
Clinical stage: BLA
Therapy area: Wet AMD
Drug types: OPH, GER
Lead product: ONS-5010
Funding: 100-500M

Drug notes:

About:

Jobs: